AssetMark Inc’s Maravai LifeSciences MRVI Stock Holding History

AssetMark Inc’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-21	Closed	-$175	–	2638
2024 Q3	$175	Buy	+21	New	+$182	﹤0.01%	2175

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

1WCM

12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

AssetMark Inc's MRVI Position: Q4 2024 in Review

AssetMark Inc sold out of Maravai LifeSciences (MRVI) in Q4 2024, closing a stake of 21 shares — an estimated $175 sold.

AssetMark Inc first reported a position in MRVI in Q3 2024 and held it in 1 quarter. The position peaked at $175 in Q3 2024. 185 funds tracked by Wall St. Rank hold MRVI as of Q4 2024.

AssetMark Inc reported no remaining Maravai LifeSciences position as of Q4 2024 after selling out during the quarter.
AssetMark Inc sold 21 Maravai LifeSciences shares in Q4 2024, an estimated $175.
AssetMark Inc first reported a position in Maravai LifeSciences in Q3 2024 and held it in 1 quarter.
AssetMark Inc's Maravai LifeSciences position peaked at $175 in Q3 2024.
185 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q4 2024.

Based on AssetMark Inc's 13F filing for Q4 2024, filed 6 Feb 2025.